Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice. (Q30376493)

21 June 2017

title

Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice. (English)

1 reference

21 June 2017

1 reference

1 reference

1 reference

Wagner Quintilio

1

1 reference

21 June 2017

Flavia S Kubrusly

2

1 reference

21 June 2017

Dmitri Iourtov

3

1 reference

21 June 2017

Cosue Miyaki

4

1 reference

21 June 2017

Maria Aparecida Sakauchi

5

1 reference

21 June 2017

Fernanda Lúcio

6

1 reference

21 June 2017

Sandra de Cássia Dias

7

1 reference

21 June 2017

Celia S Takata

8

1 reference

21 June 2017

Eliane N Miyaji

9

1 reference

21 June 2017

Hisako G Higashi

10

1 reference

21 June 2017

Luciana C C Leite

11

1 reference

21 June 2017

Isaias Raw

12

1 reference

21 June 2017

language of work or name

English

0 references

publication date

5 May 2009

1 reference

21 June 2017

1 reference

21 June 2017

volume

27

1 reference

21 June 2017

issue

31

1 reference

21 June 2017

page(s)

4219-4224

1 reference

Epidemiology of influenza

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

Seasonal and pandemic influenza: a 2007 update on challenges and solutions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

Pandemic H5N1 influenza vaccine development: an update.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

New hepatitis B vaccine formulated with an improved adjuvant system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

Immunology. The shape of things to come

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

Structural characterization of the lipid A of Bordetella pertussis 1414 endotoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

A new and improved microassay to determine 2-keto-3-deoxyoctonate in lipopolysaccharide of gram-negative bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

IgG isotype distribution of local and systemic immune responses induced by influenza virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.047

10.1016/J.VACCINE.2009.04.047

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference